Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients
Status:
Withdrawn
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This study aims to identify and describe the presence of itch active molecules in psoriasis
and response to treatment with apremilast. This data will be complemented by
immunohistochemical data determining nerve ending density and neuropeptide concentrations
before and during treatment and correlated with patient reported outcome. It is important to
underscore that itch may interfere with various aspects of patient functioning, emotions and
social status and should therefore be adequately addressed while treating patients with
psoriasis